AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
BAC   23.66 (+1.59%)
Log in

NASDAQ:SYRSSyros Pharmaceuticals Stock Price, Forecast & News

$11.47
-0.68 (-5.60 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.35
Now: $11.47
$12.39
50-Day Range
$8.60
MA: $9.71
$12.15
52-Week Range
$4.26
Now: $11.47
$12.39
Volume349,905 shs
Average Volume314,946 shs
Market Capitalization$524.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More
Syros Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.98 million
Book Value$1.87 per share

Profitability

Net Income$-75,440,000.00
Net Margins-1,950.42%

Miscellaneous

Employees76
Market Cap$524.10 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have increased by 122.7% and is now trading at $11.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syros Pharmaceuticals.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its earnings results on Thursday, May, 7th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.06. The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $1.72 million. Syros Pharmaceuticals had a negative return on equity of 84.15% and a negative net margin of 1,950.42%. View Syros Pharmaceuticals' earnings history.

What price target have analysts set for SYRS?

7 brokers have issued twelve-month target prices for Syros Pharmaceuticals' shares. Their forecasts range from $8.00 to $18.00. On average, they expect Syros Pharmaceuticals' share price to reach $13.29 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals.

Has Syros Pharmaceuticals been receiving favorable news coverage?

News headlines about SYRS stock have been trending negative this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Syros Pharmaceuticals.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $11.47.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $524.10 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.